| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2646 |
| Trial ID | NCT04834401 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1273|Elasomeran|Spikevax |
| Co-treatment | Natalizumab |
| Location approved | UK, Canada, Taiwan, Switzerland, Japan, EU, Australia, South Korea, Singapore, US |
| Recruitment status | Completed |
| Title | Evaluating the Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in People With Multiple Sclerosis |
| Year | 2021 |
| Country | United States|Puerto Rico |
| Company sponsor | St. Barnabas Medical Center |
| Other ID(s) | US-TYS-11909 |
| Vector information | |||
|
|||
| Cohort1: Natalizumab | |||||
|
|||||
| Cohort2: Fumarates | |||||
|
|||||
| Cohort3: Interferon Beta 1a | |||||
|
|||||
| Cohort4: Ocrelizumab | |||||
|
|||||